EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Immunotherapy Adherence Patterns in Melanoma Patients: A Retrospective Analysis

Eric Gan, Syril Que

Proceedings of IMPRS · 2026-03-30 · 8 (1)

DOI: 10.18060/29622 ↗

At a glance

Journal article in Proceedings of IMPRS, published online on 2026-03-30. Written by Eric Gan and 1 co-authors. The full text is freely available (open access, CC BY 4.0).

AstrattDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Immunotherapy has significantly improved outcomes for patients with melanoma, taking their median survival from 6-9 months to over 5 years. However, this is severely limited by the high discontinuation rate (50-60%). Understanding adherence factors is critical for optimizing treatment success and allows physicians to address potential complications earlier.

Methods

In this study, we performed a 5-year chart review in the Indiana University Health system through Cerner’s electronic health records. In order to determine patients with Stage III melanoma, we used ICD-10 codes C43 (malignant melanoma) and C77 (lymph node metastases). Only 28 of 75 patients reviewed satisfied the inclusion criteria. We looked at demographics, clinical features, treatment regimen, patient preferences, and discontinuation outcomes. Descriptive statistics were applied to assess adherence and discontinuation factors.

Results

Among those 28 eligible patients, 20 (71.4%) of them discontinued immunotherapy. Those who received ipilimumab-nivolumab therapy had the highest discontinuation rate while patients with nivolumab monotherapy had the lowest. Adverse effects from the treatment itself were the most common cause of discontinuation. Socioeconomic factors like time to treatment centers (mean 29.4, ± 15.9 minutes) and insurance type had no effect on discontinuation.

Conclusion

In this retrospective, single-system cohort study, it highlights that immunotherapy discontinuation is still very high in patients with melanoma, likely due to adverse effects. Socioeconomic factors, in contrast, had no effect on the discontinuation rate. Although the sample size is limited, these findings could lead to future studies with larger cohorts that could be used to inform melanoma treatment in real-world patients.

Cite

APA

Gan, E., & Que, S. (2026). Immunotherapy Adherence Patterns in Melanoma Patients: A Retrospective Analysis. Proceedings of IMPRS, 8(1). https://doi.org/10.18060/29622

Vancouver

Gan E, Que S. Immunotherapy Adherence Patterns in Melanoma Patients: A Retrospective Analysis. Proceedings of IMPRS. 2026;8(1). doi:10.18060/29622

BibTeX
@article{Gan2026,
  author = {Gan, Eric and Que, Syril},
  title = {Immunotherapy Adherence Patterns in Melanoma Patients: A Retrospective Analysis},
  journal = {Proceedings of IMPRS},
  year = {2026},
  volume = {8},
  number = {1},
  doi = {10.18060/29622}
}
Start for free →